Key result
Transarterial chemoembolization resulted in long-term improvement of blood clotting and increased survival by six months in a patient with Kasabach-Merritt syndrome caused by hepatic angiosarcoma.
Why the study?
Does transarterial chemoembolization improve blood clotting and survival in a patient with Kasabach-Merritt syndrome caused by hepatic angiosarcoma?
Case Report (n=1)
Does transarterial chemoembolization improve blood clotting and survival in a patient with Kasabach-Merritt syndrome caused by hepatic angiosarcoma?
Transarterial chemoembolization may be an effective therapy for improving coagulation and survival in patients with hepatic angiosarcoma complicated by Kasabach-Merritt syndrome.
Provides first reported regimen for hepatic angiosarcoma with KMS; leaves open confirmation before guiding practice.
Hepatic angiosarcoma is a rare disease, and hepatic hemangiosarcoma with Kasabach-Merritt syndrome (KMS) is even rarer. Although there have been several reports about KMS caused by hepatic angiosarcoma, there has been no mention of successful treatment regimens for hepatic angiosarcoma with KMS. A 64-year-old female patient presented with right upper abdominal pain and multiple cutaneous purpuras for 10 days. Blood analysis revealed that hemoglobin, platelet and fibrinogen were significantly decreased, prothrombin time was prolonged, fibrinogen degradation products were increased. Contrast-enhanced computed tomography scan of the abdomen demonstrated a large mass in the right lobe of the liver, which is pathologically suggestive of hepatic angiosarcoma. Based on the above examination, the patient was diagnosed with KMS caused by hepatic angiosarcoma. Repeated transfusion of blood products could only temporarily improve the coagulation function of the patient. After transarterial chemoembolization, the patient experienced a long-term improvement of blood clotting, and the patient's survival increased by six months. Transarterial chemoembolization should be considered one of effective therapies for hepatic angiosarcoma with KMS.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2021) conducted a case report in Kasabach-Merritt syndrome caused by hepatic angiosarcoma (n=1). Transarterial chemoembolization was evaluated on Improvement of blood clotting and survival. Transarterial chemoembolization resulted in long-term improvement of blood clotting and increased survival by six months in a patient with Kasabach-Merritt syndrome caused by hepatic angiosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: